SLXN
Silexion Therapeutics Corp
$2.74
-0.11 (-3.86%)
At close · Jul 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Under these circumstances, in accordance with the requirements of Accounting Standards Codification (“ASC”) 205-40, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$8.79M
Shares
3,330,785
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$11.91M
+27.9%
FY2025
Diluted EPS
$89.60
-97.7%
FY2025
Operating Cash Flow
-$10.82M
-28.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $185K | $155K | $28K | $153K | |
| $7.92M | $7.14M | $5.82M | $3.71M | |
| $4.81M | $4.49M | $6.76M | $973K | |
| $12.73M | $11.63M | $12.57M | $4.68M | |
| -$12.73M | -$11.63M | -$12.57M | -$4.68M | |
| $176K | $277K | $3.94M | $395K | |
| -$12.91M | -$11.91M | -$16.51M | -$5.08M | |
| — | $3000 | $10K | $32K | |
| -$12.91M | -$11.91M | -$16.52M | -$5.11M | |
| — | $0 | $76K | $166K | |
| — | $11.91M | $16.44M | $4.94M | |
| USD/shares | — | $89.60 | $3,949.40 | $6,634.50 |
| USD/shares | — | $89.60 | $3,949.40 | $6,634.50 |
| shares | — | 132.95K | 4163.5 | 744.84 |
| shares | — | 132.95K | 4163.5 | 744.84 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
0.04×
Biotechnology median 7.60×